These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy. Nagy S; Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Bieri O; Vuillerot C; Bonati U; Fischer D J Vis Exp; 2019 Jan; (143):. PubMed ID: 30688316 [TBL] [Abstract][Full Text] [Related]
6. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys. Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G; J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680 [TBL] [Abstract][Full Text] [Related]
7. The Association Between Physical Activity/Heart Rate Variability Data Obtained Using a Wearable Device and Timed Motor Functional Tests in Patients with Duchenne Muscular Dystrophy: A Pilot Study. Nakamura A; Matsumura T; Takeshima Y; Kuru S; Imazaki M; Nonomura H; Kaiya H J Neuromuscul Dis; 2024; 11(3):715-724. PubMed ID: 38607760 [TBL] [Abstract][Full Text] [Related]
8. Participation in daily life activities and its relationship to strength and functional measures in boys with Duchenne muscular dystrophy. Bendixen RM; Lott DJ; Senesac C; Mathur S; Vandenborne K Disabil Rehabil; 2014; 36(22):1918-23. PubMed ID: 24499260 [TBL] [Abstract][Full Text] [Related]
9. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Miller NF; Alfano LN; Iammarino MA; Connolly AM; Moore-Clingenpeel M; Powers BR; Tsao CY; Waldrop MA; Flanigan KM; Mendell JR; Lowes LP Pediatr Neurol; 2020 Dec; 113():15-20. PubMed ID: 32979653 [TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of timed motor performance in children with Duchenne muscular dystrophy. Martini J; Hukuda ME; Caromano FA; Favero FM; Fu C; Voos MC Physiother Theory Pract; 2015 Mar; 31(3):173-81. PubMed ID: 25539097 [TBL] [Abstract][Full Text] [Related]
11. The assisted 6-minute cycling test to assess endurance in children with a neuromuscular disorder. Jansen M; De Jong M; Coes HM; Eggermont F; Van Alfen N; De Groot IJ Muscle Nerve; 2012 Oct; 46(4):520-30. PubMed ID: 22987692 [TBL] [Abstract][Full Text] [Related]
12. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis. Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Schroeder J; Naduvilekoot Devasia A; Zuesli S; Bernert G; Laugel V; Bloetzer C; Steinlin M; Capone A; Gloor M; Tobler P; Haas T; Bieri O; Zumbrunn T; Fischer D; Bonati U Neuromuscul Disord; 2018 Jan; 28(1):16-23. PubMed ID: 29174526 [TBL] [Abstract][Full Text] [Related]
13. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy. Mayhew AG; Moat D; McDermott MP; Eagle M; Griggs RC; King WM; James MK; Muni-Lofra R; Shillington A; Gregson S; Pallant L; Skura C; Staudt LA; Eichinger K; McMurchie H; Rabb R; Di Marco M; Brown S; Zanin R; Arnoldi MT; McIntyre M; Wilson A; Alfano LN; Lowes LP; Blomgren C; Milev E; Iodice M; Pasternak A; Chiu A; Lehnert I; Claus N; Dieruf KA; Rolle E; Nicorici A; Andres B; Hobbiebrunken E; Roetmann G; Kern V; Civitello M; Vogt S; Hayes MJ; Scholtes C; Lacroix C; Gunn T; Warner S; Newman J; Barp A; Kundrat K; Kovelman S; Powers PJ; Guglieri M; Neuromuscul Disord; 2022 Jun; 32(6):460-467. PubMed ID: 35618576 [TBL] [Abstract][Full Text] [Related]
14. Jumping Mechanography is a Suitable Complementary Method to Assess Motor Function in Ambulatory Boys with Duchenne Muscular Dystrophy. Blaschek A; Rodrigues M; Rawer R; Müller C; Ille L; Schröder S; Idriess M; Müller-Felber W; Vill K Neuropediatrics; 2021 Dec; 52(6):455-461. PubMed ID: 33706402 [TBL] [Abstract][Full Text] [Related]
15. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977 [TBL] [Abstract][Full Text] [Related]
16. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Alfano LN; Miller NF; Berry KM; Yin H; Rolf KE; Flanigan KM; Mendell JR; Lowes LP Neuromuscul Disord; 2017 May; 27(5):452-457. PubMed ID: 28279570 [TBL] [Abstract][Full Text] [Related]
17. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337 [TBL] [Abstract][Full Text] [Related]
18. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information? Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815 [TBL] [Abstract][Full Text] [Related]
19. Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. Beenakker EA; Maurits NM; Fock JM; Brouwer OF; van der Hoeven JH Eur J Paediatr Neurol; 2005; 9(6):387-93. PubMed ID: 16102988 [TBL] [Abstract][Full Text] [Related]
20. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy. Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]